Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Gains from Investment Securities (2019 - 2026)

Enliven Therapeutics has reported Gains from Investment Securities over the past 8 years, most recently at $1.9 million for Q1 2026.

  • Quarterly results put Gains from Investment Securities at $1.9 million for Q1 2026, down 22.22% from a year ago — trailing twelve months through Mar 2026 was $1.9 million (down 22.22% YoY), and the annual figure for FY2025 was $4.6 million, up 14.88%.
  • Gains from Investment Securities reached $1.9 million in Q1 2026 per ELVN's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.8 million in Q1 2024 and bottomed at $501839.0 in Q2 2022.
  • Median Gains from Investment Securities over the past 5 years was $3.7 million (2025), compared with a mean of $3.6 million.
  • The largest annual shift saw Gains from Investment Securities soared 814.69% in 2022 before it plummeted 68.22% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $1.8 million in 2022, then soared by 224.42% to $6.0 million in 2023, then crashed by 33.28% to $4.0 million in 2024, then rose by 14.88% to $4.6 million in 2025, then crashed by 57.97% to $1.9 million in 2026.
  • Business Quant data shows Gains from Investment Securities for ELVN at $1.9 million in Q1 2026, $4.6 million in Q4 2025, and $3.7 million in Q3 2025.